Integrated Investment Consultants LLC Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Integrated Investment Consultants LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 17.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 720 shares of the medical research company’s stock after purchasing an additional 107 shares during the period. Integrated Investment Consultants LLC’s holdings in Thermo Fisher Scientific were worth $382,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of TMO. Halpern Financial Inc. lifted its stake in Thermo Fisher Scientific by 307.7% in the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $33,000. Live Oak Investment Partners purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $36,000. Tyler Stone Wealth Management purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth $38,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $5.22 during midday trading on Wednesday, hitting $576.78. The company had a trading volume of 136,944 shares, compared to its average volume of 1,578,999. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The company has a market cap of $219.93 billion, a price-to-earnings ratio of 36.99, a PEG ratio of 2.43 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a fifty day moving average of $567.37 and a two-hundred day moving average of $522.08.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.40 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a $0.39 dividend. The ex-dividend date is Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,277 shares of company stock valued at $28,513,384. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent research reports. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Raymond James increased their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Robert W. Baird reissued an “outperform” rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Finally, Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $599.00.

View Our Latest Research Report on TMO

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.